特别针对ABL的myristoyl口袋:用于慢性髓性白血病的STAMP抑制剂
Hiroshi Ureshino1, Shinya Kimura1,2
1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine Saga University, Saga, Japan.
Expert review of hematology
|January 7, 2026
概括
阿西米尼布是一种新型的STAMP抑制剂,通过向ABL的myristoyl口袋,为慢性髓性白血病 (CML) 提供了一种新的治疗方法. 这种全抑制剂显示出有效性和更好的耐受性,解决了传统TKI的挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性髓性白血病 (CML) 的治疗已经通过具有ATP竞争力的BCR:ABL1氨酸激酶抑制剂 (TKIs) 取得了进展.
- 挑战仍然存在,包括耐药性,不耐受性和长期毒性,特别是在需要多种治疗线路的患者中.
研究的目的:
- 审查CML中阿司明尼布的机制基础,临床前和临床证据.
- 为了比较阿西米尼布的STAMP抑制与ATP竞争性TKIs在选择性,毒性和耐药性模式方面.
- 评估阿西米尼布在晚期CML治疗中的作用以及无治疗缓解 (TFR) 的潜力.
主要方法:
- 对关键试验 (ASCEMBL,ASC4FIRST) 和现实研究的审查.
- 对分子反应深度,安全概况和抵抗机制的分析.
- 对阿西米尼布与包括波纳替尼布在内的其他TKI进行比较评估.
主要成果:
- 阿西米尼布在耐TCI或耐不耐TCI的CML中有效且耐受良好.
- 它诱导了快速和深度的分子反应,减少了目标外毒性.
- 它独特的机制在控制耐药性和毒性方面提供了潜在的优势.
结论:
- 阿西米尼布代表了CML治疗的重大进步,提供了一种新的作用机制.
- 对于患有抗性或不耐受之前的TKIs的患者来说,这是一个可行的选择.
- 进一步的研究将确定其在测序,组合和促进持久TFR的最佳使用.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K